Society for Radiation Oncology Administrators Annual Meeting

Proton Therapy: Is This Technology a Correct Fit for Your Radiation Oncology Service?

Pasadena, California

October 30, 2007

903 AIRPORT DRIVE, SUITE 3 ANN ARBOR, MICHIGAN 48108 TEL (734) 913-4000 FAX (734) 913-4318 <u>WWW.ARVINAGROUP.COM</u>

Session Presenters

Joseph M. Spallina, FAAMA, FACHE Director ARVINA GROUP, LLC Ann Arbor, Michigan jspallina@arvinagroup.com

www.arvinagroup.com

Barry W. Wessels, Ph.D. Professor and Director Division of Medical Physics and Dosimetry University Hospital Case Medical Center Cleveland, Ohio



Session Outline

- Background
- Proton Therapy Service Development Planning Framework
- Technical Evaluation
- Summary



Session Design

- Expertise and Experience:
 - Advanced
 - Practical
- Audience Mix:
 - Smaller radiation oncology service; want to understand the technical and planning considerations?
 - 3+ vault radiation oncology service; considering evaluating/planning a proton therapy service?



Learning Objectives

- Installations; existing and planned.
- Current vendors, their products, and potential technology developments.
- Disease specific applications.
- Key considerations in planning (service, facilities, operations, capital, reimbursement).
- The current state of technical characteristics regarding proton therapy.



What has and is occurring?

ARVINA GROUP, LLC

Copyright © 2007 Arvina Group, LLC - Ann Arbor, Michigan

- Mature science:
 - Recent technological and manufacturing developments are permitting the current equipment development.
- Radiation therapy delivery using protons:
 - Primary attraction is the superior properties of the radiation therapy delivery.
 - **There is debate regarding efficacy of the technology.**



- Currently five centers operating in the US:
 - A number of other centers operating internationally.
 - At least 10+ announced/planned to be operational by 2010 and most likely more after that.
- Vendors:
 - Single unit/non-scaleable:
 - Still River Systems.
 - □ Large, multiple gantry, scaleable units (including single):
 - Hitachi, IBA.
 - Additional vendors expected to enter the market:
 - Varian, other (s)?



- An expensive technology:
 - Investment:
 - \$20 million \$200 million.
 - To partner or not?
 - **Staffing:**
 - 7 10 FTE's for a single unit.
 - □ 15+ for multiple gantries.
 - Other operating costs = commensurate with the complexity of the equipment.



- An expensive technology (continued):
 - Facilities:
 - □ 3,000+ net useable square feet 4 acres.
 - Proximity to imaging and radiation medicine is important.
 - Planning team = experts required.
- Reimbursement:
 - Medicare covers more disease sites than commercial payors.
 - □ Declines in Medicare payments from 2007 2008.
 - Additional reimbursement to be gained from image guided complements.



Proton Therapy Applications 2007									
	Proton Th	erapy		Proton Therapy					
Cancer	Candidates (1)	Fractions		Candidates (1)	Fractions				
Approval: Medicare & Private/	Approval: Medicare Only								
Arteriovenous Malformation	55% - 60%	1	Breast	5% - 10%	20 - 25				
Brain & CNS	50% - 55%	30 - 35	Colorectal	55% - 60 %	20 +/-				
Intraocular Melanoma	100%	15	Head & Neck	25% - 30%	25 - 30				
Prostate	50% - 55%	35 - 40	Liver	15% - 20%	20 +/-				
1. As a % of radiation therapy	patient candidates	S.	Lung	35% - 40%	25 - 30				



What should be considered to evaluate and potentially plan a proton therapy service?




- Estimating capacity:
 - □ High cost = high expectations for operational performance.
 - **Treatment times (patient/fraction time):**
 - □ 30 45 minutes.
 - Learning curve during initial years of operation.
 - Daily operations:
 - At least six days/week.
 - At least 14 hours per day.
 - **•** Uptime = 85%.



- Estimating capacity (continued):
 - Patient mix:
 - **50% 60% Medicare (reflect your experience).**
 - **Disease mix:**
 - Reflect your market experience.
 - Regional proton therapy competition:
 - Reasonable assumptions must be made!





ARVINA GROUP, LLC

Copyright © 2007 Arvina Group, LLC - Ann Arbor, Michigan

- Reimbursement:
 - Medicare and commercial payors currently reimburse for prostate cancer, brain/CNS cancer, intraocular melanoma, and arteriovenous malformation.
 - Approved by Medicare, but not yet received full endorsement of commercial payors breast, lung, colorectal cancer, head & neck, liver.
 - □ As expected, Medicare reimbursement declining:
 - Increases the financial risk and the market size served.
 - Image guided procedures will add to reimbursement.



Medicare Proton Therapy Reimbursement (APC)

			2007		2008		% \$ CHANGE
APC	HCPC	TITLE	WEIGHT	PAYMENT	WEIGHT	PAYMENT	07 - 08
		Level I Proton Beam Radiation Therapy	18.8926	1,161.29	13.2746	845.50	-27.2%
0664	77520	Proton trmt, simple w/o comp					
0664	77522	Proton trmt, simple w/comp					
		Level II Proton Beam Radiation Therapy	22.6031	1,389.37	15.8841	1011.71	-27.2%
0667	77523	Proton trmt, intermediate					
0667	77525	Proton treatment, complex					




- Estimating demand:
 - Proton therapy for the most part substitutes for part of the IMRT/IGRT segment:
 - What will research demonstrate regarding IMRT/IGRT vs. proton therapy outcomes (short and long term) and efficacy?
 - How elastic are referrals, considering:
 - Existing provider owned investments?
 - Proximity to the nearest proton center?
 - Patient and family out of pocket expenses?
 - Reasonable assumptions must be made!
 - Population and disease specific methodology is required.

Proton Therapy Disease Speci	fic Estimates: III	ustration					Est'd		
Cancer	Cancer Incidence	% Rad'n Eligible	Radiation Candidates	% Proton Eligible (1)	Proton Candidates	% Payor Approved	Proton Patients		
Approval: Medicare & Private/Commercial Payors									
Arteriovenous Malformation				55% - 60%		95.0%			
Brain & CNS				50% - 55%		95.0%			
Intraocular Melanoma				100%		95.0%			
Prostate				50% - 55%		95.0%			
Approval: Medicare Only									
Breast				5% - 10%		50.0%			
Colorectal				55% - 60 %		50.0%			
Head & Neck				25% - 30%		50.0%			
Liver				15% - 20%		50.0%			
Lung				35% - 40%		50.0%			
1. As a % of radiation therapy	candidates.								




Estimating Proton Therapy Demand: Illustration



ARVINA GROUP, LLC

Copyright © 2007 Arvina Group, LLC - Ann Arbor, Michigan



- Strategic business plan:
 - Must be prepared; critical review and analysis required; must include:
 - Technology selection.
 - Project costs, working capital, partners (if any), and sources of funds.
 - Business organization.
 - Demand estimates and sensitivity analyses.
 - Operating assumptions and capacity.
 - Start up and operating costs.
 - Reimbursement and sensitivity analyses.
 - ROI analysis.
 - Marketing and referral relationship strategies.

What do we know, what have we learned, and what can we expect regarding the science and technology surrounding proton therapy?